Dimopoulos, Meletios A.

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hájek, R., Kim, K., Grosicki, S., Sia, H., et al. (2025) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Bustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35

Genomic landscape of multiple myeloma and its precursor conditions

Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 32

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Bahlis, N., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kim, K., Takezako, N., Moreau, P., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21

Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?

Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 19

VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Moreau, P., Dimopoulos, M. A. C., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Casca, F., Mace, S., et al. (2022) · Annals of Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18